July 13 (Reuters) - Nuvo Pharmaceuticals Inc NRI.TO
* Nuvo Pharmaceuticals Inc. announces Pennsaid 2 percent
phase 3 trial to support regulatory approvals in the E.U.,
Canada and Australia
* Will conduct a new placebo-controlled, multi-centre phase
3 trial in Germany to study Pennsaid 2 percent for treatment of
acute ankle sprains
Source text for Eikon: ID:nPnF7C47a
Further company coverage: NRI.TO